We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
- Authors
Hsu, C-H; Yang, T-S; Hsu, C; Toh, H C; Epstein, R J; Hsiao, L-T; Chen, P-J; Lin, Z-Z; Chao, T-Y; Cheng, A-L
- Abstract
Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population.
- Publication
British journal of cancer, 2010, Vol 102, Issue 6, p981
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6605580